VanEck has launched a genomics and healthcare innovators ETF, offering investors access to a range of companies across these themes.
The VanEck Genomics and Healthcare Innovators UCITS ETF, launched today (7 September) on London Stock Exchange and Deutsche Börse Xetra, will provide investors with exposure to companies operating across genomics and digitalisation, genomics companies being those examining the interaction between genes and gene products. Martijn Rozemuller, CEO at VanEck Europe, explained that genetic treatments, while once considered experimental and expensive, were becoming more affordable and common and that although the genomics industry was still in early stages, the space offered potential growth o...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
